Takeda's Actos Could Face Pending Fate Of Rival's Diabetes Drug
This article was originally published in PharmAsia News
Takeda Pharmaceutical could lose U.S. sales of its blockbuster Actos (pioglitazone) if a U.S. FDA review of the drug links it with an increased risk of bladder cancer
You may also be interested in...
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.